You are here

Therapeutic Potential and Targeted Homing of ECSOD-MSCs in Animal Model of Mucositi

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DE024410-01A1
Agency Tracking Number: R43DE024410
Amount: $224,932.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDCR
Solicitation Number: PA13-234
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
*(FY14 USE 10008420)
CARLSBAD, CA 92011-4402
United States
DUNS: 617462234
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (760) 434-8646
Business Contact
Phone: (760) 434-8646
Research Institution

DESCRIPTION (provided by applicant): In the present submission we are requesting funding to support studies designed to assess proof-of-concept for a novel cell-based approach that possesses the potential to concurrently address multiple pathobiologic mechanisms initiated by chemo- + high dose irradiation. The importance of this effort is underscored by fact that oral mucositis is a common side effect of chemo- and radiotherapy especially in patients receiving head and neck radiation. More specifically, ithas been estimated that nearly 40% of all patients treated with standard doses of chemotherapy experience some degree of mucositis while nearly all patients undergoing high-dose chemotherapy experience this debilitating side effect. Despite key advances, such as clinical guidelines and increased understanding of the molecular pathways leading to targeted therapeutics mucositis continues to represent an important medical need in many oncology patients especially with recently emergent molecularly targeted

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government